Pfizer reports positive top-line results from Phase 3 pain study of ALO-02
Study ALO-02-10-3001 included adult patients with moderate-to-severe chronic non-cancer pain lasting at least three months and requiring a continuous around-the-clock opioid analgesic for an extended period of time.